Acadia Pharmaceuticals | ACAD - Net Income



Acadia Pharmaceuticals reported $26.67M in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
ALKERMES USD 87.1M 64.63M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Biogen USD 634.8M 394.3M Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Bristol-Myers Squibb USD 1.31B 1.15B Jun/2025
Corcept Therapeutics USD 35.15M 14.6M Jun/2025
Cytokinetics USD -134370000 27.01M Jun/2025
Eisai JPY 14.47B 13.52B Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Incyte USD 405M 246.8M Jun/2025
J&J USD 5.54B 5.46B Jun/2025
Moderna USD -825000000 146M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Pfizer USD 2.91B 58M Jun/2025
Prothena USD -125770000 67.81M Jun/2025
PTC Therapeutics USD -64849000 931.41M Jun/2025
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025